Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for COVID-19 pneumonia
ChiCTR2000029868Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in coronavirus pneumonia (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Viral nucleic acid test and Adverse events. Started Feb 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000029868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029868.